1. Home
  2. QNCX vs LCTX Comparison

QNCX vs LCTX Comparison

Compare QNCX & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QNCX
  • LCTX
  • Stock Information
  • Founded
  • QNCX 2012
  • LCTX 1990
  • Country
  • QNCX United States
  • LCTX United States
  • Employees
  • QNCX N/A
  • LCTX N/A
  • Industry
  • QNCX Biotechnology: Biological Products (No Diagnostic Substances)
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • QNCX Health Care
  • LCTX Health Care
  • Exchange
  • QNCX Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • QNCX 92.3M
  • LCTX 110.2M
  • IPO Year
  • QNCX 2019
  • LCTX N/A
  • Fundamental
  • Price
  • QNCX $1.79
  • LCTX $0.55
  • Analyst Decision
  • QNCX Strong Buy
  • LCTX Strong Buy
  • Analyst Count
  • QNCX 4
  • LCTX 4
  • Target Price
  • QNCX $9.50
  • LCTX $5.25
  • AVG Volume (30 Days)
  • QNCX 280.9K
  • LCTX 3.9M
  • Earning Date
  • QNCX 11-13-2024
  • LCTX 11-14-2024
  • Dividend Yield
  • QNCX N/A
  • LCTX N/A
  • EPS Growth
  • QNCX N/A
  • LCTX N/A
  • EPS
  • QNCX N/A
  • LCTX N/A
  • Revenue
  • QNCX N/A
  • LCTX $8,719,000.00
  • Revenue This Year
  • QNCX N/A
  • LCTX N/A
  • Revenue Next Year
  • QNCX N/A
  • LCTX $123.52
  • P/E Ratio
  • QNCX N/A
  • LCTX N/A
  • Revenue Growth
  • QNCX N/A
  • LCTX N/A
  • 52 Week Low
  • QNCX $0.51
  • LCTX $0.48
  • 52 Week High
  • QNCX $2.45
  • LCTX $1.61
  • Technical
  • Relative Strength Index (RSI)
  • QNCX 45.75
  • LCTX 41.03
  • Support Level
  • QNCX $1.80
  • LCTX $0.48
  • Resistance Level
  • QNCX $2.00
  • LCTX $0.57
  • Average True Range (ATR)
  • QNCX 0.21
  • LCTX 0.05
  • MACD
  • QNCX -0.06
  • LCTX 0.01
  • Stochastic Oscillator
  • QNCX 8.14
  • LCTX 48.36

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: